Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447

Microenvironmental regulation of tumor progression and metastasis

Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994

Oncology meets immunology: the cancer-immunity cycle.

Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929

Cancer immunotherapy using checkpoint blockade

Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791

Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer

Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198

Understanding the tumor immune microenvironment (TIME) for effective therapy

Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials

Chu, X., Tian, W., Wang, Z., Zhang, J., & Zhou, R. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01800-3 · Cited by 232

Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance

Ashrafi, A., Akter, Z., Modareszadeh, P., Modareszadeh, P., Berisha, E., Alemi, P. S., Castro, M. D. C. C., Deese, A. R., & Li, Z. (2022) · Cancers · doi:10.3390/cancers14194562 · Cited by 200

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Li, Y., Mao, T., Wang, J., Zheng, H., Hu, Z., Cao, P., Yang, S., Zhu, L., Guo, S., Zhao, X., et al. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01082-8 · Cited by 120

Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial

Jiang, T., Wang, P., Zhang, J., Zhao, Y., Zhou, J., Fan, Y., Shu, Y., Liu, X., Zhang, H., He, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00751-9 · Cited by 95

Cancer-associated fibroblasts in non-small cell lung cancer: Recent advances and future perspectives

Zhang, H., Jiang, H., Zhu, L., Li, J., & Ma, S. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.05.009 · Cited by 86

Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10

Huang, M., Chen, Y., Lyu, W.-Y., He, X., Ye, Z.-H., Huang, C.-Y., He, X., Chen, X., Chen, X., Zhang, B., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106988 · Cited by 70

Taurine enhances the antitumor efficacy of PD-1 antibody by boosting CD8+ T cell function

Yü, P., Shan, J., Liu, Y., Liu, F., Wang, L., Liu, Z., Li, J., Yue, D., Wang, L., Chen, X., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03308-z · Cited by 67

CD39 inhibition and VISTA blockade may overcome radiotherapy resistance by targeting exhausted CD8+ T cells and immunosuppressive myeloid cells

Zhang, Y., Hu, J., Ji, K., Jiang, S., Dong, Y., Sun, L., Wang, J., Hu, G., Chen, D., Chen, K., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101151 · Cited by 63

Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy

Chen, M., Bie, L., & Ying, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115514 · Cited by 60

Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer

Yang, Z., Wu, G., Zhang, X., Gao, J., Meng, C., Liu, Y., Wei, Q., Sun, L., Wei, P., Bai, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001444 · Cited by 56

Drug-loaded microbubble delivery system to enhance PD-L1 blockade immunotherapy with remodeling immune microenvironment

Zheng, J., Huang, J., Zhang, L., Wang, M., Xu, L., Dou, X., Leng, X., Fang, M., Sun, Y., & Wang, Z. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00350-5 · Cited by 54

Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells

Chen, Y., He, X., Lu, Q., Shi, W., Yuan, L., Huang, M., Xu, Y., Chen, X., Gu, L., Zhang, L., et al. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114940 · Cited by 48

Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination

Sun, Z., Mai, H., Xue, C., Fan, Z., Li, J., Chen, H., Huo, N., Kang, X., Tang, C., Fang, L., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007415 · Cited by 48

Anti-PD-L1 antibody alleviates pulmonary fibrosis by inducing autophagy via inhibition of the PI3K/Akt/mTOR pathway

Lu, Y., Zhong, W., Liu, Y., chen, W., zhang, J., Zeng, Z., Huang, H., qiao, Y., Wan, X., Meng, X., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108504 · Cited by 48

Radiological artificial intelligence - predicting personalized immunotherapy outcomes in lung cancer

Roisman, L. C., Kian, W., Anoze, A., Fuchs, V., Spector, M., Steiner, R., Kassel, L., Rechnitzer, G., Fried, I., Peled, N., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00473-x · Cited by 43

Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing Data to Establish and Validate a Prognostic Model for Patients With Lung Adenocarcinoma

Jiang, A., Wang, J., Liu, N., Zheng, X., Li, Y., Ma, Y., Zheng, H., Chen, X., Fan, C., Zhang, R., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.833797 · Cited by 42

Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives

Ye, Z.-H., Yu, W., Huang, M., Chen, J., & Lu, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.12.016 · Cited by 41

A Spatial Quantitative Systems Pharmacology Platform spQSP-IO for Simulations of Tumor–Immune Interactions and Effects of Checkpoint Inhibitor Immunotherapy

Gong, C., Ruiz-Martínez, Á., Kimko, H. H. C., & Popel, A. S. (2021) · Cancers · doi:10.3390/cancers13153751 · Cited by 38

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC

Bie, F., Tian, H., Sun, N., Zang, R., Zhang, M., Song, P., Liu, L., Peng, Y., Bai, G., Zhou, B., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.769124 · Cited by 39

Blockade of T‐cell receptor with Ig and ITIM domains elicits potent antitumor immunity in naturally occurring HBV‐related HCC in mice

Wu, Y., Hao, X., Wei, H., Sun, R., Chen, Y., & Tian, Z. (2022) · Hepatology · doi:10.1002/hep.32715 · Cited by 35

Modern therapies of nonsmall cell lung cancer

Jachowski, A., Marcinkowski, M., Szydłowski, J., Grabarczyk, O., Nogaj, Z., Marcin, L. P., Pławski, A., Jagodziński, P. P., & Słowikowski, B. K. (2023) · Journal of Applied Genetics · doi:10.1007/s13353-023-00786-4 · Cited by 36

Single-cell RNA sequencing reveals enhanced antitumor immunity after combined application of PD-1 inhibitor and Shenmai injection in non-small cell lung cancer

Yu, D., Yang, P., Lu, X., Huang, S., Liu, L., & Fan, X. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01184-3 · Cited by 31

Research Progress on Nanoparticles-Based CRISPR/Cas9 System for Targeted Therapy of Tumors

Nie, D., Guo, T., Yue, M., Li, W., Zong, X., Zhu, Y., Huang, J., & Lin, M. (2022) · Biomolecules · doi:10.3390/biom12091239 · Cited by 33

Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy

Godiyal, Y., Maheshwari, D., Taniguchi, H., Zinzuwadia, S. S., Díaz, Y. M., Tewari, D., & Bishayee, A. (2024) · Military Medical Research · doi:10.1186/s40779-024-00586-9 · Cited by 35

Immunology and immunotherapy in gastric cancer

Xu, X., Chen, J., Li, W., Feng, C., Liu, Q., Gao, W., & He, M. S. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01104-2 · Cited by 28

TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Lin, A., Zhang, H., Meng, H., Deng, Z., Gu, T., Luo, P., & Zhang, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.667875 · Cited by 27

Sex Difference of Colon Adenoma Pathway and Colorectal Carcinogenesis

Choi, Y., & Kim, N. (2023) · The World Journal of Men s Health · doi:10.5534/wjmh.230085 · Cited by 31

A target map of clinical combination therapies in oncology: an analysis of clinicaltrials.gov

Yang, J., Kang, H., Lyu, L., Xiong, W., & Yuanjia, H. (2023) · Discover Oncology · doi:10.1007/s12672-023-00758-4 · Cited by 29

Molecular basis, potential biomarkers, and future prospects of OSCC and PD-1/PD-L1 related immunotherapy methods

Cheng, Y., Song, Z., Chen, J., Tang, Z., & Wang, B. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e25895 · Cited by 26

PD ‐1: A critical player and target for immune normalization

Liu, X., Zhao, A., Xiao, S., Li, H., Li, M., Guo, W., & Han, Q. (2024) · Immunology · doi:10.1111/imm.13755 · Cited by 27

Sintilimab, stereotactic body radiotherapy and granulocyte–macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial

Ni, J., Zhou, Y., Wu, L., Ai, X., Dong, X., Chu, Q., Han, C., Wang, X., & Zhu, Z. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01905-3 · Cited by 25

GAPDH Is a Novel Ferroptosis-Related Marker and Correlates with Immune Microenvironment in Lung Adenocarcinoma

Ouyang, X., Zhu, R., Lin, L., Wang, X., Zhuang, Q., & Hu, D. (2023) · Metabolites · doi:10.3390/metabo13020142 · Cited by 24

P2X7 receptor promotes migration and invasion of non-small cell lung cancer A549 cells through the PI3K/Akt pathways

Bai, X., Li, Q., Peng, X., Li, X., Qiao, C., Tang, Y., & Zhao, R. (2023) · Purinergic Signalling · doi:10.1007/s11302-023-09928-z · Cited by 25

Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment

Song, L., Wang, X., Wang, C., Wu, Y. M., Liu, M., Liu, R., Zhang, S., Hong, X., Liu, H., Tai, X., et al. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01796-w · Cited by 23

Contribution of skeletal muscle to cancer immunotherapy: A focus on muscle function, inflammation, and microbiota

Deng, Y., Zhao, L., Huang, X., Zeng, Y., Xiong, Z., & Zuo, M. (2022) · Nutrition · doi:10.1016/j.nut.2022.111829 · Cited by 27

New prospects of cancer therapy based on pyroptosis and pyroptosis inducers

Chen, Q., Sun, Y., Wang, S., & Xu, J. (2023) · APOPTOSIS · doi:10.1007/s10495-023-01906-5 · Cited by 23

HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs—A Long Way to the Top

Aliaga, P. T., Spitaleri, G., Attili, I., Corvaja, C., Battaiotto, E., Angelopoulos, P. A., Signore, E. D., Passaro, A., & de Marinis, F. (2025) · Molecules · doi:10.3390/molecules30122645 · Cited by 22

SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer

Zhao, J., Yu, X., Huang, D., Ma, Z., Gao, B., Cui, J., Chu, Q., Zhou, Q. H., Sun, M., Day, D., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006055 · Cited by 22

Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor Microenvironment

Ailia, M. J., Heo, J., & Yoo, S. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076495 · Cited by 22

Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy

Jia, L., Chen, N., Chen, X., Niu, C. S., Liu, Z., Ma, K., Wang, N., Yang, L., Zhao, Y., Song, W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1074906 · Cited by 21

Sintilimab plus Bronchial Arterial Infusion Chemotherapy/Drug-Eluting Embolic Chemoembolization for Advanced Non–Small Cell Lung Cancer: A Preliminary Study of 10 Patients

Li, Y., Guo, R., Bie, Z., Li, B., & Li, X. (2021) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2021.08.019 · Cited by 20

Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study

Chu, X., Qiang, H., Xie, M., Li, X., Zhao, J., Wu, Y., Zhou, J., Ye, J., Zhao, C., Han, C., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03100-5 · Cited by 19

High expression of PD-L1 mainly occurs in non-small cell lung cancer patients with squamous cell carcinoma or poor differentiation

LIU, L. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.028227 · Cited by 19

Liposomal honokiol inhibits non-small cell lung cancer progression and enhances PD-1 blockade via suppressing M2 macrophages polarization

Cheng, Y., Han, X., Lai, X., & Wei, X. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156093 · Cited by 22

Preliminary anticancer evaluation of new Pd(II) complexes bearing NNO donor ligands

Hussain, S., Hussain, S., Zafar, M. N., Hussain, I., Khan, F., Mughal, E. U., & Tahir, M. N. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.101915 · Cited by 20

Establishing a Proteomics-Based Signature of AKR1C3-Related Genes for Predicting the Prognosis of Prostate Cancer

Cui, X., Li, C., Ding, J., Yao, Z., Zhao, T., Guo, J., Wang, Y., & Li, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054513 · Cited by 17

Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study

Dou, X.-J., Ma, R.-Y., Ren, D.-W., Liu, Q., & Yan, P. (2024) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s444884 · Cited by 16

Effect of JAK/STAT signaling on anti-PD-L1 immunotherapy efficacy in lung cancer

Yao, Y., Tao, G., Xie, D., Xu, Y., & Liang, L. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104861 · Cited by 16

Comprehensive Analysis of Programmed Cell Death Signature in the Prognosis, Tumor Microenvironment and Drug Sensitivity in Lung Adenocarcinoma

Pan, S., Meng, H., Fan, T. T., Hao, B., Song, C., Li, D., Li, N., & Geng, Q. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.900159 · Cited by 16

Identification of a ceRNA Network in Lung Adenocarcinoma Based on Integration Analysis of Tumor-Associated Macrophage Signature Genes

Zhang, L., Zhang, K., Liu, S., Zhang, R., Yang, Y., Wang, Q., Zhao, S., Li, Y., Zhang, Y., & Wang, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.629941 · Cited by 15

Claudin-7 deficiency induces metabolic reprogramming of neutrophils in the colorectal cancer microenvironment

Liang, X., Yuan, D., Zhao, S., Zhou, J., Wang, K., Liu, X., Liu, Y., Li, H., Hao, M., Huang, W., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08064-3 · Cited by 14

Effects of ESCO2 or its methylation on the prognosis, clinical characteristics, immune microenvironment, and pathogenesis of low-grade glioma

Liu, Z., Cheng, X., Pang, B., Wang, S., Liu, B., Chen, C., Qian, R., Liang, W., Zhu, Y., Li, P., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108399 · Cited by 14

Treatment response, survival, and safety profile of camrelizumab plus apatinib regimen as third-line treatment in metastatic gastric cancer patients

Ma, N., Qiao, H., Tao, H., Gan, X., Shan, Z., Chen, X., & Zhou, X. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.101962 · Cited by 13

METTL14 regulates CD8+T-cell activation and immune responses to anti‐PD‐1 therapy in lung cancer

Sun, C., Wang, J., Li, H., Liu, L., Lin, Y., Zhang, L., Zu, X., Zhu, Y., Shu, Y., Shen, D., et al. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-024-03402-9 · Cited by 13

Tumor Microenvironment Heterogeneity-Based Score System Predicts Clinical Prognosis and Response to Immune Checkpoint Blockade in Multiple Colorectal Cancer Cohorts

Wang, H., Li, Z., Ou, S., Song, Y., Luo, K., Guan, Z., Zhao, L., Huang, R., & Yu, S. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.884839 · Cited by 13

Application of Nanoparticles in Tumour Targeted Drug Delivery and Vaccine

Tu, Y., Yao, Z., Yang, W., Tao, S., Li, B., Wang, Y., Su, Z., & Li, S. (2022) · Frontiers in Nanotechnology · doi:10.3389/fnano.2022.948705 · Cited by 13

Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death‐ligand 1 inhibitors in non–small cell lung cancer

Villaruz, L. C., Blumenschein, G. R., Otterson, G. A., & Leal, T. A. B. (2023) · Cancer · doi:10.1002/cncr.34683 · Cited by 12

First‐line immune‐based combination therapies for advanced non‐small cell lung cancer: A Bayesian network meta‐analysis

Mao, Z., Jiang, P., Zhang, Y., Li, Y., Jia, X., Wang, Q., Jiao, M., Jiang, L., Shen, Y. L., & Guo, H. (2021) · Cancer Medicine · doi:10.1002/cam4.4405 · Cited by 10

A Novel PD-L1-Containing MSLN Targeting Vaccine for Lung Cancer Immunotherapy

Zeng, W., Pan, J., Huang, M., Fang, Z., Jia, J., Dong, J., Zhong, H., He, J., Zhong, H., He, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.925217 · Cited by 11

Ultrasound -Induced Thermal Effect Enhances the Efficacy of Chemotherapy and Immunotherapy in Tumor Treatment

Xiang, Y., Tang, L. C., Pang, H., Han, X., He, Y., Feng, Y., Ju, L., Zhang, L., & Wang, D. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s464830 · Cited by 13

GPRC5A is a potential prognostic biomarker and correlates with immune cell infiltration in non-small cell lung cancer

Lin, Y., Wang, Y., Xue, Q., Zheng, Q., Chen, L., Yan, J., Huang, Z., & Li, Y. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-739 · Cited by 10

Interfacial Peptides as Affinity Modulating Agents of Protein-Protein Interactions

Ershov, P. V., Mezentsev, Y. V., & Ivanov, A. S. (2022) · Biomolecules · doi:10.3390/biom12010106 · Cited by 11

Optimization of cancer immunotherapy on the basis of programmed death ligand‐1 distribution and function

Zou, W., Luo, X., Gao, M., Chang, Y., Wan, X., Yu, S., Wu, Y., Wang, A., Fenical, W., Wei, Z., et al. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16054 · Cited by 12

Siglec 15 as a biomarker or a druggable molecule for non-small cell lung cancer

Moreira, R. S., da Silva, M. M., Vasconcelos, C. F. D. M., da Silva, T. D., Cordeiro, G. G., Mattos, L. A. R., Pitta, M. G. D. R., Rêgo, M. J. B. D. M., & Pereira, M. C. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05437-z · Cited by 9

An On‐Treatment Decreased Trend of Serum IL‐6 and IL‐8 as Predictive Markers Quickly Reflects Short‐Term Efficacy of PD‐1 Blockade Immunochemotherapy in Patients with Advanced Gastric Cancer

Liu, J., Mao, Y., Mao, C., Wang, D., Dong, L., & Zhu, W. (2024) · Journal of Immunology Research · doi:10.1155/2024/3604935 · Cited by 9

Dynamic surveillance of lymphocyte subsets in patients with non-small cell lung cancer during chemotherapy or combination immunotherapy for early prediction of efficacy

Zhen, S., Wang, W., Qin, G., Lu, T., Li, Y., & Zhang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1316778 · Cited by 11

β-elemene inhibits tumor-promoting in small cell lung cancer by affecting M2 macrophages and TGF-β

Huang, W., Fu, B., & Xu, H. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03533-z · Cited by 8

Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment

Li, F., Liao, B.-C., Wang, T., Qi, T., & Wang, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.918709 · Cited by 8

Therapeutic Potential of Targeting Transforming Growth Factor-beta (TGF-β) and Programmed Death-ligand 1 (PD-L1) in Pancreatic Cancer

Pourali, G., Zafari, N., Velayati, M., Mehrabadi, S., Maftooh, M., Hassanian, S. M., Mobarhan, M. G., Ferns, G. A., Avan, A., & Khazaei, M. (2023) · Current Drug Targets · doi:10.2174/0113894501264450231129042256 · Cited by 9

Advancements in nanomedicine delivery systems: unraveling immune regulation strategies for tumor immunotherapy

Zhang, Y., Chen, X., Hu, B., Zou, B., & Xu, Y. (2024) · Nanomedicine · doi:10.1080/17435889.2024.2374230 · Cited by 8

LSD1 inhibition sensitizes anti-PD1 blockade immunotherapy by inhibiting the long-range attack of tumor-derived extracellular vesicles

Zhao, Y., Zhang, D., Meng, L., Shan, S., Zhang, C., Deng, Z., Han, C., & Kong, L. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.10.030 · Cited by 7

Plasma Immune Proteins and Circulating Tumor DNA Predict the Clinical Outcome for Non-Small-Cell Lung Cancer Treated with an Immune Checkpoint Inhibitor

Stensgaard, S., Thomsen, A., Helstrup, S., Meldgaard, P., & Sørensen, B. S. (2023) · Cancers · doi:10.3390/cancers15235628 · Cited by 6

Prognosis and immunotherapy significances of a cancer-associated fibroblasts-related gene signature in lung adenocarcinoma

Luo, Y., Zhang, S., Xie, H., Su, Q., He, S., & Lei, Z. (2023) · Cellular and Molecular Biology · doi:10.14715/cmb/2023.69.14.9 · Cited by 6

Solid Phase Synthesis, DFT Calculations, Molecular Docking, and Biological Studies of Symmetrical N2,N4,N6-Trisubstituted-1,3,5-triazines

Akbar, W., Ehsan, S., Siddique, S. A., Sarfraz, M., Shaheen, F., Shafqat, A., Shahnaz, Siddique, M. B. A., Saeed, A., Al‐Salahi, R. A., et al. (2024) · ACS Omega · doi:10.1021/acsomega.4c01980 · Cited by 6

Development of a Novel Pyroptosis-Associated lncRNA Biomarker Signature in Lung Adenocarcinoma

Wang, P., Wang, Z., Lin, Y., Castellano, L., Stebbing, J., Zhu, L., & Peng, L. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00757-4 · Cited by 6

Anthraquinones from the roots of Morinda scabrida Craib exhibit antiproliferative activity against A549 lung cancer cells and antitubulin polymerization

Sae-Lim, S., Ngiwsara, L., Lirdprapamongkol, K., Puttamuk, T., Maneeanakekul, S., Thangsan, P., Sangsuwan, W., Svasti, J., & Chuawong, P. (2023) · Fitoterapia · doi:10.1016/j.fitote.2023.105781 · Cited by 6

Construction and analysis of a lysosome-dependent cell death score-based prediction model for non-small cell lung cancer

Fu, J., Chen, Y. S., Li, J., Tan, M., Lin, R., Wang, J., Wu, G., Rao, Y., Wu, F., Gao, Y., et al. (2024) · Discover Oncology · doi:10.1007/s12672-024-01233-4 · Cited by 5

Identification of STAT3 phosphorylation inhibitors using generative deep learning, virtual screening, molecular dynamics simulations, and biological evaluation for non-small cell lung cancer therapy

Cai, W., Jiang, B., Yin, Y., Ma, L., Li, T., & Chen, J. (2024) · Molecular Diversity · doi:10.1007/s11030-024-11067-5 · Cited by 5

Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial)

Liu, X., Sui, X.-Y., Xu, Y., Yang, F., Wu, S., Zhu, X.-Z., Zuo, K., Cao, S.-W., Jin, X., Chen, L., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02505-5 · Cited by 4

Integrated Bulk and Single-cell RNA Sequencing Data Constructs and Validates a Prognostic Model for Non-small Cell Lung Cancer

Zhu, J., Yang, J., Chen, X., Wang, Y., Wang, X., Zhao, M., Li, G., Wang, Y., Zhu, Y., Yan, F., et al. (2024) · Journal of Cancer · doi:10.7150/jca.90768 · Cited by 4

The anticancer mechanisms of Toxoplasma gondii rhoptry protein 16 on lung adenocarcinoma cells

Li, G., Li, Q., Tong, Y., Zeng, J., Dang, T., Yang, N., Zhou, Y., Ma, L., Ge, Q. Y., & Zhao, Z. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2392902 · Cited by 4

Establishment and Validation of an Interferon-Stimulated Genes (ISGs) Prognostic Signature in Pan-cancer Patients: A Multicenter, Real-world Study

Zhou, Z., Zheng, Y., Mo, S., Li, S., Zheng, X., Wei, R., Fan, T. T., Chen, T., Xiao, C., Li, C., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.71385 · Cited by 4

PMSG-Net: A priori-guided multilevel graph transformer fusion network for immunotherapy efficacy prediction

Yang, W., Wu, W., Wang, L., Zhang, S., Zhao, J.-J., & Qiang, Y. (2023) · Comput. Biol. Medicine · doi:10.1016/j.compbiomed.2023.107371 · Cited by 4

Dihydrotanshinone I inhibits PHGDH to suppress serine synthesis and remodel TME in NSCLC

Qian, C., Han, H., Wan, L., Huang, Y., Luo, Y., Wang, Z., Peng, C., Gao, M., Fan, W., Lu, Y., et al. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158366 · Cited by 3

Dual blockade of GSTK1 and CD47 improves macrophage-mediated phagocytosis on cancer cells

Yu, W., Ye, Z.-H., Shi, J.-J., Deng, W.-Q., Chen, J., & Lu, J. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116898 · Cited by 3

Osimertinib Induces the Opposite Effect of Proliferation and Migration in the Drug Resistance of EGFR-T790M Non-small Cell Lung Cancer Cells

Wang, R.-H., Chang, C., Chen, C., Liu, K., & Chao, J. (2023) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520623666230223111217 · Cited by 3

Discovery of a novel ROS-based signature for predicting prognosis and immunosuppressive tumor microenvironment in lung adenocarcinoma

Guo, Y., Chang, G., Wan, R., Zhang, X., Ma, Z., Bai, H., & Wang, J. (2024) · Journal of Cancer · doi:10.7150/jca.93975 · Cited by 4

Research progress of anti-tumor active ingredients in Dandelion

Xie, J., Huang, Y., & Wang, Q. (2020) · Journal of Oncology Research · doi:10.30564/jor.v2i2.2472 · Cited by 3

A computational chemistry-based approach to optimizing PD-1/PD-L1 inhibitors

Zhai, M., Ji, S., Hu, H., Wu, Y., Shi, Y., Zhu, R., Jiang, Y., & Yang, Y. (2025) · Frontiers in Chemistry · doi:10.3389/fchem.2024.1533541 · Cited by 2

Targeting the Toll-like Receptor Signaling Pathway in Lung Cancer: Therapeutic Opportunities and Challenges

Usama, M., Raza, B., Wu, M., & Ji, S. (1970) · Current Drug Targets · doi:10.2174/0113894501414090250903070446 · Cited by 2

Accurate diagnosis of triple-negative breast cancer enables temperature-compensation all optical microfibre gratings system

Liu, X., Xu, Q., Wang, Y., Wang, C., Liang, W., Huang, L., Lü, L., Lv, J., Gao, J., Yu, B., et al. (2026) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2026.118706 · Cited by 2

The efficacy and safety of first‑line anti‑PD‑1/PD‑L1 immunotherapy for gastric esophageal cancer: A systematic review and meta‑analysis of phase III randomized controlled trials

Duan, X., Du, H., Qi, R., Yuan, M., & Shi, J. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11915 · Cited by 2

Durvalumab and taxane family combination therapy enhances the antitumoral effects for NSCLC: An in vitro study

Firoozi, M., Sadeghi‐Mohammadi, S., Asadi, M., Shekari, N., Nejad, F. S., Alizade‐Harakiyan, M., Soleimani, Z., & Zarredar, H. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3919 · Cited by 2

Antibiotic adoption effects on nutrition and quality of life in lung cancer patients undergoing radiotherapy and chemotherapy: A meta-analysis

Zhao, Z., & Yua, Y. (2024) · Technology and Health Care · doi:10.3233/thc-240660 · Cited by 2

Unraveling tumoral heterogeneity and angiogenesis-associated mechanisms of PD-1 and LAG-3 dual inhibition in lung cancers by single-cell RNA sequencing

Zhao, L., Tang, C., Jin, X. S., Wang, H., Xu, K., Liu, X., Liu, Y., Zhao, W., Zhang, W., Ye, L., et al. (2025) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2025.02.004 · Cited by 2

Construction of a prognostic risk model based on pyroptosis-related genes and comprehensive analysis of key genes and tumor immune microenvironment for colon cancer

Liu, M., Zhang, J., Zhao, Y., & Zhang, X. (2024) · Medicine · doi:10.1097/md.0000000000039300 · Cited by 1

Immunotherapy in advanced colorectal cancer: Current landscape, mechanisms, challenges, and future directions

Huang, J., & Tian, G. (2026) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552251414845 · Cited by 1

[Combination therapy based on PD-1/PD-L1 blocking in the treatment of non-small cell lung cancer].

Zhang, N., Wang, X., Shen, J., Sun, S., Shen, Y., & Wang, J. (2022) · PubMed

Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies

Sui, H., Ma, N., Wang, Y., Li, H., Liu, X., Su, Y., & Yang, J. (2018) · Journal of Immunology Research · doi:10.1155/2018/6984948 · Cited by 207

Advances in PD-1 inhibitor combination therapy for non-small cell lung cancer

Wang, F. (2025) · MedScien · doi:10.61173/vsnwe981

Combining chemotherapy with PD-1 blockade in NSCLC

Mathew, M., Enzler, T., Shu, C. A., & Rizvi, N. A. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.01.003 · Cited by 147

Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non–Small-Cell Lung Cancer: Where Do We Stand?

Qiao, M., Jiang, T., Ren, S., & Zhou, C. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.06.005 · Cited by 53